Senior writer Tina Hesman Saey is a geneticist-turned-science writer who covers all things microscopic and a few too big to be viewed under a microscope. She is an honors graduate of the University of Nebraska-Lincoln where she did research on tobacco plants and ethanol-producing bacteria. She spent a year as a Fulbright scholar at the Georg-August University in Göttingen, Germany, studying microbiology and traveling. Her work on how yeast turn on and off one gene earned her a Ph.D. in molecular genetics at Washington University in St. Louis. Tina then rounded out her degree collection with a master’s in science journalism from Boston University. She interned at the Dallas Morning News and Science News before returning to St. Louis to cover biotechnology, genetics and medical science for the St. Louis Post-Dispatch. After a seven year stint as a newspaper reporter, she returned to Science News. Her work has been honored by the National Academies of Sciences, Engineering and Medicine, the Endocrine Society, the Genetics Society of America and by journalism organizations.
Trustworthy journalism comes at a price.
Scientists and journalists share a core belief in questioning, observing and verifying to reach the truth. Science News reports on crucial research and discovery across science disciplines. We need your financial support to make it happen – every contribution makes a difference.
All Stories by Tina Hesman Saey
-
Health & Medicine
FDA and CDC OK resuming J&J COVID-19 shots paused over rare clot concerns
The single-dose vaccine carries a low risk of rare blood clots in women under 50, but experts say its benefits outweigh that risk.
-
Health & Medicine
Experts predict U.S. COVID-19 cases will dip in summer but surge in winter
Masks, vaccines and coronavirus variants could all affect how bad a predicted winter surge gets.
-
Health & Medicine
The P.1 coronavirus variant is twice as transmissible as earlier strains
The variant first found in Brazil can evade some immunity from previous COVID-19 infections, making reinfections a possibility.
-
Humans
New depictions of ancient hominids aim to overcome artistic biases
Artists’ intuition instead of science drive most facial reconstructions of extinct species. Some researchers hope to change that.
-
Health & Medicine
Moderna and Pfizer COVID-19 vaccines may block infection as well as disease
The mRNA vaccines are about 90 percent effective at blocking coronavirus infection, which could lead to reduced transmission, real-world data suggest.
-
Health & Medicine
Here’s what makes 4 promising COVID-19 vaccines unique — and potentially useful
More vaccines still in the works are exploring a variety of approaches, including pills and electrical zaps.
-
Health & Medicine
The COVID-19 pandemic is now a year old. What have scientists learned?
As we enter the pandemic’s second year, researchers share what they’ve learned and what they look forward to.
-
Health & Medicine
People fully vaccinated against COVID-19 can socialize without masks, CDC says
Two weeks after their final COVID-19 shot, people can visit other vaccinated people indoors without masks or physical distancing.
-
Health & Medicine
Most pro athletes who got COVID-19 didn’t develop heart inflammation
Few professional athletes developed heart inflammation after a bout of COVID-19, but how the findings relate to the general public isn’t clear.
-
Genetics
DNA databases are too white, so genetics doesn’t help everyone. How do we fix that?
A lack of diversity in genetic databases is making precision medicine ineffective for many people. One historian proposes a solution: construct reference genomes for individual populations.
-
Health & Medicine
People who have had COVID-19 might need only one shot of a coronavirus vaccine
Antibody levels in health care workers who had COVID-19 and got vaccinated were more than 500 times higher than those vaccinated but never infected.
-
Health & Medicine
What you need to know about J&J’s newly authorized one-shot COVID-19 vaccine
Even as a third COVID-19 vaccine becomes available in the United States, questions remain over how well it works and if people will take it.